Alphatec Holdings (ATEC) and HTG Molecular Diagnostics (HTGM) Critical Comparison

Alphatec Holdings (NASDAQ: ATEC) and HTG Molecular Diagnostics (NASDAQ:HTGM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitabiliy, earnings, analyst recommendations and risk.

Earnings and Valuation

This table compares Alphatec Holdings and HTG Molecular Diagnostics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Alphatec Holdings N/A N/A N/A ($3.37) -0.55
HTG Molecular Diagnostics $5.64 million 4.76 -$21.68 million ($3.39) -0.83

Alphatec Holdings has higher revenue, but lower earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Alphatec Holdings, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

20.8% of Alphatec Holdings shares are held by institutional investors. Comparatively, 31.3% of HTG Molecular Diagnostics shares are held by institutional investors. 23.6% of Alphatec Holdings shares are held by insiders. Comparatively, 8.1% of HTG Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Alphatec Holdings and HTG Molecular Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alphatec Holdings -23.27% N/A -29.46%
HTG Molecular Diagnostics -440.31% -1,538.49% -117.27%

Analyst Recommendations

This is a summary of recent recommendations for Alphatec Holdings and HTG Molecular Diagnostics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alphatec Holdings 0 0 0 0 N/A
HTG Molecular Diagnostics 0 1 2 0 2.67

HTG Molecular Diagnostics has a consensus price target of $5.83, indicating a potential upside of 106.86%. Given HTG Molecular Diagnostics’ higher probable upside, analysts plainly believe HTG Molecular Diagnostics is more favorable than Alphatec Holdings.

Volatility and Risk

Alphatec Holdings has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, HTG Molecular Diagnostics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Summary

Alphatec Holdings beats HTG Molecular Diagnostics on 6 of the 10 factors compared between the two stocks.

About Alphatec Holdings

Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

Receive News & Ratings for Alphatec Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.